Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock

被引:62
|
作者
Hohn, Andreas [1 ]
Schroeder, Stefan [2 ]
Gehrt, Anna [3 ]
Bernhardt, Kathrin [3 ]
Bein, Berthold [4 ]
Wegscheider, Karl [5 ]
Hochreiter, Marcel [6 ]
机构
[1] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Anaesthesiol Intens Care Palliat Care & Pain, D-44789 Bochum, Germany
[2] Hosp Duren Gem GmbH, Dept Anaesthesiol Intens Care Med & Pain Therapy, D-52351 Duren, Germany
[3] West Coast Hosp, Dept Anesthesiol & Intens Care Med, D-25746 Heide, Germany
[4] Univ Hosp Schleswig Holstein, Dept Anesthesiol & Intens Care Med, D-24105 Kiel, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany
[6] Univ Heidelberg Hosp, Dept Anesthesiol, D-69120 Heidelberg, Germany
关键词
Procalcitonin; Sepsis; Economical outcomes; Intensive care; RESPIRATORY-TRACT INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE PATIENTS; ANTIMICROBIAL RESISTANCE; DISEASES-SOCIETY; CONTROLLED-TRIAL; DURATION; GUIDELINES; EPIDEMIOLOGY; INITIATION;
D O I
10.1186/1471-2334-13-158
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Procalcitonin (PCT)-protocols to guide antibiotic treatment in severe infections are known to be effective. But less is known about the long-term effects of such protocols on antibiotic consumption under real life conditions. This retrospective study analyses the effects on antibiotic use in patients with severe sepsis and septic shock after implementation of a PCT-protocol. Methods: We conducted a retrospective ICU-database search for adult patients between 2005 and 2009 with sepsis and organ dysfunction who where treated accordingly to a PCT-guided algorithm as follows: Daily measurements of PCT (BRAHMS PCT LIA (R); BRAHMS Aktiengesellschaft, Hennigsdorf, Germany). Antibiotic therapy was discontinued if 1) clinical signs and symptoms of infection improved and PCT decreased to <= 1 ng/ml, or 2) if the PCT value was >1 ng/ml, but had dropped to 25-35% of the initial value within three days. The primary outcome parameters were: antibiotic days on ICU, ICU re-infection rate, 28-day mortality rate, length of stay (LOS) in ICU, mean antibiotic costs (per patient) and ventilation hours. Data from 141 patients were included in our study. Primary outcome parameters were analysed using covariance analyses (ANCOVA) to control for effects by gender, age, SAPS II, APACHE II and effective cost weight. Results: From baseline data of 2005, duration of antibiotic therapy was reduced by an average of 1.0 day per year from 14.3 +/- 1.2 to 9.0 +/- 1.7 days in 2009 (p=0.02). ICU re-infection rate was decreased by yearly 35.1% (95% CI -53 to -8.5; p=0.014) just as ventilation hours by 42 hours per year (95% CI -72.6 to -11.4; p=0.008). ICU-LOS was reduced by 2.7 days per year (p<0.001). Trends towards an average yearly reduction of 28-day mortality by -22.4% (95% CI -44.3 to 8.1; p=0.133) and mean cost for antibiotic therapy/patient by -14.3 Euro (95% CI -55.7 to 27.1) did not reach statistical significance. Conclusions: In a real-life clinical setting, implementation of a PCT-protocol was associated with a reduced duration of antibiotic therapy in septic ICU patients without compromising clinical or economical outcomes.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock
    Andreas Hohn
    Stefan Schroeder
    Anna Gehrt
    Kathrin Bernhardt
    Berthold Bein
    Karl Wegscheider
    Marcel Hochreiter
    BMC Infectious Diseases, 13
  • [2] Effects of a procalcitonin-guided protocol on length of antibiotic therapy in patients with severe sepsis and septic shock
    Hohn, A.
    Schroeder, S.
    INFECTION, 2013, 41 : S34 - S34
  • [3] Procalcitonin-guided therapy in severe sepsis and septic shock
    Wan-Jie Gu
    Jing-Chen Liu
    Critical Care, 18 (3):
  • [4] Procalcitonin-guided therapy in severe sepsis and septic shock
    Gu, Wan-Jie
    Liu, Jing-Chen
    CRITICAL CARE, 2014, 18 (03):
  • [5] EVALUATION OF PROCALCITONIN-GUIDED ANTIBIOTIC THERAPY IN SEPSIS AND SEPTIC SHOCK
    Popa, Andreea
    Hoffman, Brian
    Tumbush, Courtney
    Hejal, Rana
    Lemonovich, Tracy
    Armitage, Keith
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 617 - 617
  • [6] Procalcitonin-guided therapy in severe sepsis and septic shock Response
    Schlattmann, Peter
    Brunkhorst, Frank M.
    CRITICAL CARE, 2014, 18 (03):
  • [7] Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock
    Andreas Hohn
    Nina Balfer
    Bernhard Heising
    Sabine Hertel
    Jan C. Wiemer
    Marcel Hochreiter
    Stefan Schröder
    Annals of Intensive Care, 8
  • [8] Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock
    Hohn, Andreas
    Balfer, Nina
    Heising, Bernhard
    Hertel, Sabine
    Wiemer, Jan C.
    Hochreiter, Marcel
    Schroeder, Stefan
    ANNALS OF INTENSIVE CARE, 2018, 8
  • [9] Potential Confounders of Procalcitonin-Guided Antibiotic Therapy for Sepsis
    Kikutani, Kazuya
    Ohshimo, Shinichiro
    Shime, Nobuaki
    CRITICAL CARE MEDICINE, 2017, 45 (12) : e1310 - e1311
  • [10] Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock A Randomized Clinical Trial
    Bloos, Frank
    Trips, Evelyn
    Nierhaus, Axel
    Briegel, Josef
    Heyland, Daren K.
    Jaschinski, Ulrich
    Moerer, Onnen
    Weyland, Andreas
    Marx, Gernot
    Gruendling, Matthias
    Kluge, Stefan
    Kaufmann, Ines
    Ott, Klaus
    Quintel, Michael
    Jelschen, Florian
    Meybohm, Patrick
    Rademacher, Sibylle
    Meier-Hellmann, Andreas
    Utzolino, Stefan
    Kaisers, Udo X.
    Putensen, Christian
    Elke, Gunnar
    Ragaller, Maximilian
    Gerlach, Herwig
    Ludewig, Katrin
    Kiehntopf, Michael
    Bogatsch, Holger
    Engel, Christoph
    Brunkhorst, Frank M.
    Loeffler, Markus
    Reinhart, Konrad
    JAMA INTERNAL MEDICINE, 2016, 176 (09) : 1266 - 1276